Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

A. Elkrief, P. Joubert, M. Florescu, M. Tehfe, N. Blais, B. Routy

Abstract


Lung cancer is the most commonly diagnosed cancer in Canada and remains associated with high mortality. Never- theless, recent advances in the fields of immuno-oncology and precision medicine have led to significant improve- ments in clinical outcome in metastatic non-small-cell lung cancer (nsclc). Those improvements were facilitated by a greater understanding of the biologic classification of nsclc, which catalyzed discoveries of novel therapies. Here, we present a comprehensive review of the recent avalanche of practice-changing trials in metastatic nsclc, and we offer an approach to the management of this disease from a Canadian perspective. We begin with an overview of the pathologic and molecular characterization of metastatic nsclc. Next, we review the indications for currently approved immune checkpoint inhibitors, and we provide an approach to the management of disease with a driver mutation. Finally, we address future avenues in both diagnostics and therapeutics for patients with advanced and metastatic nsclc.


Keywords


Lung Cancer; Immunotherapy; Targeted therapy; Chemotherapy Biomarker

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.27.5953






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)